Related Experiment Video
Updated: Jun 14, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Blockade of renin-angiotensin system attenuates advanced glycation end products-mediated signaling pathways
Masashi Kamioka1, Toshiyuki Ishibashi, Koichi Sugimoto
1Department of Cardiology and Hematology, Fukushima Medical University, Fukushima, Japan.
Aim:
Advanced glycation end products (AGE) and a receptor for AGE (RAGE) play a key role in diabetic vascular complications. Matrix metalloproteinases (MMPs) and apoptosis contribute to plaque instability. The renin-angiotensin system (RAS) is crucial for NADPH oxidase-dependent redox signaling pathways in the vascular wall. We investigated the effects of RAS blockade on AGE-triggered signaling pathways and its downstream events, including MMP-9 and apoptosis.
Methods:
We used cultured rabbit aortic smooth muscle cells (SMCs), which were stimulated with AGE in the presence or absence of temocaprilat or olmesartan.
Results:
Angiotensin converting enzyme (ACE) mRNA levels were increased 4 to 6 hours after adding AGE. AGE induced Rac1 and p47(phox) membrane translocation, reactive oxygen species (ROS) generation and NF-kappaB phosphorylation within 15 minutes, and various molecular expressions after 18 hours, which were attenuated by RAS blockade by temocaprilat or olmesartan. AGE-induced RAGE expression, as well as other molecules, including membrane type 1-MMP (MT1-MMP), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1), was NADPH oxidase signaling-dependent and blunted by temocaprilat and olmesartan. The parameters of plaque instability, including MMP-9 expression and activity, and apoptosis were up-regulated by AGE, which was markedly attenuated by temocaprilat or olmesartan. Using isolated human monocyte culture, AGE-induced ROS generation and molecular expression were also attenuated by RAS blockade.
Conclusion:
The present study shows that AGE-triggered NADPH oxidase signaling pathways, including MMP-9 and apoptosis, were attenuated by RAS blockade, which may be an attractive strategy for treating plaque instability in diabetic vascular complications.
Insights
Renin-angiotensin system (RAS) blockade effectively reduces advanced glycation end product (AGE)-induced plaque instability by inhibiting NADPH oxidase signaling, MMP-9, and apoptosis in diabetic vascular complications.
Area of Science:
- Vascular Biology
- Diabetic Complications
- Pharmacology
Background:
- Advanced glycation end products (AGE) and their receptor (RAGE) are implicated in diabetic vascular complications.
- Matrix metalloproteinases (MMPs) and apoptosis contribute to atherosclerotic plaque instability.
- The renin-angiotensin system (RAS) is integral to vascular redox signaling via NADPH oxidase.
Purpose of the Study:
- To investigate the impact of RAS blockade on AGE-induced signaling pathways.
- To determine the effects of RAS blockade on MMP-9 and apoptosis in vascular smooth muscle cells.
Main Methods:
- Cultured rabbit aortic smooth muscle cells (SMCs) were stimulated with AGE.
- Cells were treated with RAS blockers temocaprilat or olmesartan.
- NADPH oxidase activity, ROS generation, NF-kappaB phosphorylation, MMP-9, and apoptosis were assessed.
Main Results:
- AGE increased ACE mRNA, Rac1/p47(phox) translocation, ROS generation, and NF-kappaB phosphorylation.
- RAS blockade attenuated AGE-induced RAGE, MT1-MMP, MCP-1, and PAI-1 expression.
- AGE-induced MMP-9 expression/activity and apoptosis were significantly reduced by RAS blockade.
Conclusions:
- RAS blockade effectively inhibits AGE-triggered NADPH oxidase signaling pathways.
- RAS blockade attenuates MMP-9 and apoptosis, key factors in plaque instability.
- RAS blockade presents a potential therapeutic strategy for diabetic vascular complications.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Diabetic Nephropathy
Hypertension II: Pathophysiology
